McCune Albright Syndrome
6
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study
Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry
DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)
Effectiveness of Medical Management of Fibrous Dysplasia of Bone.
Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome